STOCK TITAN

Shuttle Pharmaceuticals Holdings, Inc. - SHPH STOCK NEWS

Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on Shuttle Pharmaceuticals Holdings stock.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is a clinical stage pharmaceutical company pioneering innovative therapies aimed at curing cancers. Founded in 2012 by faculty members from Georgetown University Medical Center, Shuttle Pharma focuses on developing radiation sensitizers to enhance the efficacy of radiation therapy (RT). The company’s mission is to improve cancer treatment outcomes, prolong patient survival, and elevate the quality of life for those undergoing therapy.

Shuttle Pharma's flagship product, Ropidoxuridine (IPdR), is a leading candidate designed to be used in combination with RT for treating glioblastoma, a lethal brain tumor currently without a cure. The company has received positive feedback from the U.S. Food and Drug Administration (FDA), including a 'Safe to Proceed' letter, enabling the commencement of Phase II clinical trials. The FDA's guidance has paved the way for Shuttle Pharma to develop Ropidoxuridine further as a radiation sensitizer.

In addition to Ropidoxuridine, Shuttle Pharma is advancing its predictive biomarker program for prostate cancer. This initiative includes licensing intellectual property from Georgetown University to develop diagnostic blood tests. These tests aim to predict the success or failure of RT in prostate cancer patients, thereby informing treatment decisions and improving patient management.

Shuttle Pharma operates with a strong collaborative ethos, partnering with academic institutions and leveraging grant funding from entities like the National Institutes of Health (NIH). The company’s research also extends to histone deacetylase (HDAC) inhibitors, such as its lead HDAC6 inhibitor candidate, SP-2-225, which aims to prevent tumor relapse and enhance antitumor immune responses.

Financially, Shuttle Pharma is actively involved in capital raising initiatives to support its ambitious research and development goals. A recent Rights Offering aims to raise up to $4.5 million, supplementing the company’s resources to advance its clinical trials and diagnostic programs.

Overall, Shuttle Pharmaceuticals Holdings, Inc. is at the forefront of developing groundbreaking therapies that could revolutionize cancer treatment by making radiation therapy more effective and less toxic.

Rhea-AI Summary

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced pricing of a $4.5 million public offering priced at-the-market. The offering includes up to 2,950,820 shares of common stock (or pre-funded warrants) and warrants at $1.525 per share and accompanying warrant. The warrants, exercisable at $1.40 per share, will expire in five years. Net proceeds will fund IND-enabling and Phase I/II clinical trials, including $2.3 million payment to Theradex Systems for Phase II trials of Ropidoxuridine. The offering is expected to close around October 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Shuttle Pharmaceuticals (Nasdaq: SHPH) has fully paid off its Senior Secured Convertible Note issued in January 2023, which had an initial balance of $4.3 million. The company made $1.3 million in cash payments and issued 1,094,970 shares, bringing total outstanding shares to 2,946,099. In October 2024, the company secured $790,000 in gross proceeds through a convertible note and warrant offering, including $237,500 from CEO Dr. Anatoly Dritschilo.

The company is advancing its Phase 2 clinical trial for glioblastoma treatment, with five out of six trial sites ready to begin treating patients. The trial will initially include 40 patients randomized into two dose groups, with plans to add 14 more patients once the optimal dose is determined. The trial is expected to complete in 18-24 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Shuttle Pharmaceuticals (Nasdaq: SHPH) has initiated patient dosing in its Phase 2 Clinical Trial of Ropidoxuridine, a radiation sensitizer for treating glioblastoma brain tumors. The trial involves 40 patients initially randomized into two dosage groups (1,200 mg/day and 960 mg/day), with plans to add 14 more patients once the optimal dose is determined. The study targets IDH wild-type, methylation negative glioblastoma patients, who currently have treatment options with radiation therapy. The trial is expected to complete in 18-24 months. Ropidoxuridine has received FDA Orphan Drug Designation, potentially providing marketing exclusivity upon approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.34%
Tags
Rhea-AI Summary

Shuttle Pharmaceuticals (Nasdaq: SHPH) has completed enrollment of six clinical trial sites for its Phase 2 study of Ropidoxuridine, a radiation sensitizer for treating glioblastoma. The trial sites include Georgetown University Medical Center, UNC Medical Center, UVA Cancer Center, John Theurer Cancer Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute. The study will randomize 40 patients into two dose groups (1,200 mg/day and 960 mg/day) to determine optimal dosing, followed by an additional 14 patients for survival endpoint comparison. The trial is expected to complete in 18-24 months. Ropidoxuridine has received FDA Orphan Drug Designation for brain tumor treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.34%
Tags
-
Rhea-AI Summary

Shuttle Pharmaceuticals (Nasdaq: SHPH) announced its CEO, Dr. Anatoly Dritschilo, will present at the 2024 ThinkEquity Conference on October 30, 2024, at 8:30 am ET. The presentation will highlight updates on the company's Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment and plans for Shuttle Diagnostics to develop predictive biomarkers for prostate cancer radiation therapy outcomes.

The conference will be held at the Mandarin Oriental Hotel in New York, featuring one-on-one meetings with investors. The presentation will be accessible via webcast through the company's website and the conference platform. Shuttle Pharmaceuticals focuses on improving outcomes for cancer patients treated with radiation therapy by developing radiation sensitizers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
conferences
-
Rhea-AI Summary

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has expanded its Phase 2 clinical trial for Ropidoxuridine, a radiation sensitizer for treating glioblastoma patients. The company has added two more site locations, bringing the total to four out of six planned sites ready to enroll patients. These include UVA Cancer Center, John Theurer Cancer Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute.

The trial targets IDH wild-type, methylation negative glioblastoma patients, aiming to improve outcomes for this aggressive brain cancer. Ropidoxuridine has received Orphan Drug Designation from the FDA. The study will initially enroll 40 patients, testing two dosage levels, with an additional 14 patients added later to achieve statistical significance. Shuttle Pharma expects the trial to be completed in 18 to 24 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
Rhea-AI Summary

Shuttle Pharmaceuticals, a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, has announced the issuance of U.S. Patent No. 12,077,515 for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease. The patent, issued on September 3, 2024, covers a series of selective HDAC inhibitors designed to modulate gene expression involved in cancer progression and immune responses.

This patent strengthens Shuttle Pharma's intellectual property portfolio, supporting its efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes. The company's HDAC platform aims to develop cancer immunotherapies and has potential applications in autoimmune, inflammatory, metabolic, neurological, and infectious diseases. Shuttle Pharma now holds over 20 composition of matter HDAC inhibitor patents in the U.S., Canada, and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.44%
Tags
none
-
Rhea-AI Summary

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has provided a corporate update for Q2 2024. Key highlights include:

1. Enrollment has begun in the Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment.
2. Two out of six planned site locations are ready to treat patients.
3. Shuttle Pharma received FDA Orphan Drug Designation for Ropidoxuridine.
4. The trial will involve 40 patients initially, with an additional 14 patients once the optimal dose is determined.
5. The company has regained compliance with Nasdaq's Listing Rule 5250(c) after filing delayed financial reports.

Shuttle Pharma aims to improve outcomes for cancer patients treated with radiation therapy by developing radiation sensitizers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.44%
Tags
-
Rhea-AI Summary

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has announced that it has regained compliance with Nasdaq's Minimum Bid Price Rule. The company's stock traded above $1.00 per share for ten consecutive trading days, meeting the requirement as of August 27, 2024. Shuttle Pharma, founded in 2012 by Georgetown University Medical Center faculty members, is a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy.

The company's mission is to develop radiation sensitizers that enhance the effectiveness of radiation therapy while reducing side effects. Shuttle Pharma aims to increase cancer cure rates, prolong patient survival, and improve quality of life when used as a primary treatment or in combination with other therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.02%
Tags
none
Rhea-AI Summary

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has received a notice of non-compliance from Nasdaq due to its failure to timely file its Q2 2024 Quarterly Report. This non-compliance stems from an ongoing re-audit of the company's 2022 financial statements, necessitated by SEC sanctions against its former auditor. Shuttle Pharma is preparing amended reports for 2023 and Q1 2024, which will include restated 2022 financials.

The company expects to file these reports soon, followed by the Q2 2024 report, to regain compliance automatically. If more time is needed, Shuttle Pharma has 60 days to submit a compliance plan to Nasdaq and could receive up to 180 days to regain compliance. The notice does not immediately affect the company's Nasdaq Capital Market listing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.45%
Tags
none

FAQ

What is the current stock price of Shuttle Pharmaceuticals Holdings (SHPH)?

The current stock price of Shuttle Pharmaceuticals Holdings (SHPH) is $1.245 as of November 6, 2024.

What is the market cap of Shuttle Pharmaceuticals Holdings (SHPH)?

The market cap of Shuttle Pharmaceuticals Holdings (SHPH) is approximately 3.7M.

What does Shuttle Pharmaceuticals Holdings, Inc. specialize in?

Shuttle Pharmaceuticals specializes in developing innovative cancer therapies, particularly radiation sensitizers, to improve the outcomes of radiation therapy.

What is Ropidoxuridine?

Ropidoxuridine (IPdR) is Shuttle Pharma's lead radiation sensitizer candidate designed to be used in combination with radiation therapy to treat glioblastoma.

What is the significance of the FDA's 'Safe to Proceed' letter for Shuttle Pharmaceuticals?

The FDA's 'Safe to Proceed' letter allows Shuttle Pharmaceuticals to commence its Phase II clinical trial for Ropidoxuridine, marking a critical step in its development.

How is Shuttle Pharmaceuticals advancing prostate cancer treatment?

Shuttle Pharmaceuticals is developing predictive diagnostic blood tests for prostate cancer to inform treatment decisions and improve patient outcomes.

What types of cancer therapies is Shuttle Pharma developing?

Shuttle Pharma is developing radiation sensitizers, predictive biomarkers, and HDAC inhibitors to enhance cancer treatment effectiveness and patient quality of life.

What collaboration does Shuttle Pharma have with Georgetown University?

Shuttle Pharma collaborates with Georgetown University, licensing intellectual property to advance its predictive biomarker program for prostate cancer.

What are the financial strategies of Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals raises capital through initiatives like Rights Offerings to fund its research and development programs, including clinical trials and diagnostic advancements.

What is the company's mission?

Shuttle Pharmaceuticals' mission is to improve cancer patients' lives by developing therapies that maximize the effectiveness of radiation therapy while minimizing side effects.

What other cancers besides glioblastoma is Shuttle Pharma targeting?

Shuttle Pharma is also targeting prostate cancer through its predictive biomarker program and diagnostic test development.

How does Shuttle Pharma contribute to the field of cancer research?

Shuttle Pharma contributes by developing novel therapies, collaborating with academic institutions, and leveraging grant funding to advance cancer treatment research.

Shuttle Pharmaceuticals Holdings, Inc.

Nasdaq:SHPH

SHPH Rankings

SHPH Stock Data

3.68M
3.34M
41.75%
1.73%
1.14%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG